pharma · Acute myeloid leukemia · Juvenile idiopathic arthritis
Istituto Gentili Italia
Istituto Gentili S.r.l.
Istituto Gentili S.r.l is a pharma organization headquartered in MILANO, IT. Primary therapeutic focus areas include Acute myeloid leukemia, Juvenile idiopathic arthritis, Malignant Pleural Mesothelioma, Osteogenesis Imp
Company details
- Status
- Public
- HQ
- Via San Giuseppe Cottolengo, 15, Milano, Lombardia 20143, IT
- Founded
- 1917
- Employees
- 121
- Programs
- 50
- Drugs
- 114
- Patents
- 0
CYCLOPHOSPHAMIDE for Inoperable locally advanced or…
Phase 2 · small molecule · Inoperable locally advanced or metastatic TNBC patients, previously treated with anti-PD-L1/PD1- regimens
CYCLOPHOSPHAMIDE for Inoperable locally advanced or… for Inoperable locally advanced or metastatic TNBC patients, previously treated with anti-PD-L1/PD1- regimens is a Phase 2 program (small_molecule) at Istituto Gentili S.r.l. with 1 ClinicalTrials.gov record(s).
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Istituto Gentili S.r.l.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Inoperable locally advanced or metastatic TNBC patients, previously treated with anti-PD-L1/PD1- regimens
- Status
- active
- Trials
- 1